Generic Name: Venetoclax
Brand Name: Venclexta
Manufacturer: AbbVie Corporation
Therapeutic Area: Acute myeloid leukemia
Indications: Venclexta is indicated, in combination with a hypomethylating agent or in combination with low-dose cytarabine, in adult patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
Manufacturer Requested Reimbursement Criteria1: In combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
Submission Type: Initial
Tumour Type: Leukemia
NOC Status at Filing: Post NOC
Project Status: Received
Companion Diagnostics: No
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient/clinician input open | December 03, 2020 |
| Call for patient/clinician input closed | January 29, 2021 |
| Submission received | January 08, 2021 |
| Submission accepted | - |
| Clarification: - Submission was not accepted for review on 22 Jan 21 | |